

Brompton Global Healthcare Income & Growth ETF
Summary of Investment Portfolio as at June 30, 2020

Total Net Asset Value \$ 54,292,885

| Portfolio Composition | % of Portfolio | % of Net Asset Value |
|----------------------------------|-----------------------|-----------------------------|
| North America | | |
| United States | | |
| Healthcare equipment | 20.7% | 21.1% |
| Pharmaceuticals | 19.8% | 20.2% |
| Biotechnology | 9.2% | 9.3% |
| Managed healthcare | 7.3% | 7.5% |
| Life sciences tools and services | 6.1% | 6.2% |
| Total North America | 63.1% | 64.3% |
| Europe | | |
| Denmark | | |
| Pharmaceuticals | 3.5% | 3.6% |
| France | | |
| Pharmaceuticals | 4.0% | 4.1% |
| Germany | | |
| Pharmaceuticals | 3.6% | 3.7% |
| Great Britain | | |
| Pharmaceuticals | 6.4% | 6.5% |
| Ireland | | |
| Healthcare equipment | 7.2% | 7.3% |
| Switzerland | | |
| Pharmaceuticals | 8.1% | 8.2% |
| Total Europe | 32.8% | 33.4% |
| Cash and short-term investments | 4.1% | 4.1% |
| Total Investment Portfolio | 100.0% | 101.8% |
| Other net liabilities | | (1.8%) |
| Total Net Asset Value | | 100.0% |

| Top 25 Holdings | % of Portfolio | % of Net Asset Value |
|---------------------------------|-----------------------|-----------------------------|
| AstraZeneca PLC | 4.4% | 4.5% |
| Roche Holding AG | 4.3% | 4.4% |
| Abbvie Inc | 4.2% | 4.3% |
| Thermo Fisher Scientific Inc | 4.2% | 4.3% |
| Abbott Laboratories | 4.1% | 4.2% |
| Cash and short-term investments | 4.1% | 4.1% |
| Sanofi SA | 4.1% | 4.1% |
| Humana Inc | 4.0% | 4.1% |
| Eli Lilly and Co | 4.0% | 4.0% |
| Steris plc | 3.9% | 4.0% |
| Novartis AG | 3.8% | 3.9% |
| Zoetis Inc | 3.8% | 3.8% |
| Becton Dickinson and Co | 3.7% | 3.8% |
| Edwards Lifesciences Corp | 3.7% | 3.8% |
| Baxter International Inc | 3.6% | 3.7% |
| Merck KGaA | 3.6% | 3.7% |
| Bristol-Myers Squibb Co | 3.6% | 3.6% |
| Novo Nordisk A/S | 3.5% | 3.6% |
| Johnson & Johnson | 3.5% | 3.5% |
| Pfizer Inc | 3.4% | 3.5% |
| UnitedHealth Group Inc | 3.3% | 3.4% |
| Medtronic PLC | 3.3% | 3.3% |
| Amgen Inc | 3.3% | 3.3% |
| GlaxoSmithKline PLC | 2.0% | 2.1% |
| Stryker Corp | 1.9% | 1.9% |
| Total | 91.3% | 92.9% |

The investment portfolio may change due to ongoing portfolio transactions of the investment fund. Quarterly updates are available on the Fund's website at www.bromptongroup.com within 60 days of each quarter end.